Peer-reviewed veterinary case report
Blood clotting test results in dogs with epilepsy on phenobarbital
By García, R et al.·Published in Veterinary clinical pathology·2024·Hospital Clí, Spain·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Thromboelastography in dogs with idiopathic epilepsy treated with phenobarbital monotherapy.
- Species:
- dog
Plain-English summary
A group of dogs with idiopathic epilepsy (a type of seizure disorder) were treated with phenobarbital, a common medication, to see how it affected their blood clotting. The study found that while most dogs didn't show major issues with blood clotting, nearly half had increased fibrinolysis, which means their bodies were breaking down blood clots more than usual. No bleeding problems were reported, but some dogs had elevated liver enzymes, suggesting potential liver effects from the medication. More research is needed to understand the significance of these findings and how they might affect treatment.
People also search for: dog epilepsy treatment phenobarbital · dog blood clotting issues · why is my dog having seizures · dog liver enzyme levels · phenobarbital side effects in dogs
Abstract
BACKGROUND: Thromboelastography (TEG) is an effective technique to assess the efficiency of coagulation. Phenobarbital (PB) can induce hematological and coagulation disorders in both animals and humans, but its effects on hemostasis have been little investigated and are poorly understood in dogs. OBJECTIVES: The aim of this article was to assess coagulation using TEG in a population of dogs with idiopathic epilepsy treated with PB. MATERIAL AND METHODS: Prospective observational study. TEG was performed in blood samples from dogs with idiopathic epilepsy that were divided in three groups: Two groups of treated dogs that were on phenobarbital treatment for less or more than 6 months, and a control group of healthy dogs. Duration of treatment, dose, phenobarbital serum concentration and selected hematological and biochemical parameters were evaluated and correlated with the TEG results. RESULTS: No statistically significant differences were found between groups. None of the animals appeared to be in a hypo- or hypercoagulable state, however 9/19 (47,4%) dogs were classified as hyper-fibrinolytic. A statistically significant negative relationship between MA and G values and increased fibrinolytic activity (LY30) were found. No statistically significant relationship was found between PB dose or PB blood levels and TEG parameters in either group. No bleeding complications were observed. DISCUSSION: The rise in fibrinolysis might be due to hepatic damage from PB, as indicated by elevated liver enzymes in many dogs with abnormal fibrinolytic patterns. Although TEG showed hyperfibrinolysis in some dogs, the presence of primary or secondary hyperfibrinolysis could not be confirmed due to the lack of D-dimer measurements and liver biopsy. TEG's sensitivity compared to other fibrinolysis biomarkers like PAP might also affect results. CONCLUSIONS: TThe cause of hyperfibrinolysis in epileptic dogs treated with phenobarbital remains unclear, with potential links to hepatic effects or handling, and further research is needed to assess its clinical significance.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/39307760/